cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Compugen Ltd
4 own
15 watching
Current Price
$0.98
$0.02
(1.86%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
84.52M
52-Week High
52-Week High
3.57
52-Week Low
52-Week Low
0.51
Average Volume
Average Volume
0.34M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization84.52M
icon52-Week High3.57
icon52-Week Low0.51
iconAverage Volume0.34M
iconDividend Yield--
iconP/E Ratio--
What does the Compugen Ltd do?
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Read More
News & Events about Compugen Ltd.
Ticker Report
2 months ago
Compugen Ltd. (NASDAQ:CGEN Get Rating) has been given a consensus recommendation of Moderate Buy by the six brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued...
PR Newswire
3 months ago
Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients Compugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune...
PR Newswire
3 months ago
Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients PR Newswire HOLON, Israel, Nov. 7, 2022 Anti-tumor activity following blockade of PVRIG with COM701 when added to nivolumab is...
Ticker Report
5 months ago
StockNews.com downgraded shares of Compugen (NASDAQ:CGEN Get Rating) from a hold rating to a sell rating in a report published on Friday. Several other brokerages have also issued reports on CGEN. Jefferies Financial Group lowered Compugen from a buy rating to a hold rating and set a $2.00 ...
Ticker Report
8 months ago
Raymond James Associates raised its holdings in Compugen Ltd. (NASDAQ:CGEN Get Rating) by 5.4% in the 4th quarter, according to its most recent 13F filing with the Securities Exchange Commission. The firm owned 213,510 shares of the biotechnology companys stock after ...
Frequently Asked Questions
Frequently Asked Questions
What is Compugen Ltd share price today?
plus_minus_icon
Can Indians buy Compugen Ltd shares?
plus_minus_icon
How can I buy Compugen Ltd shares from India?
plus_minus_icon
Can Fractional shares of Compugen Ltd be purchased?
plus_minus_icon
What are the documents required to start investing in Compugen Ltd stocks?
plus_minus_icon
What is today’s traded volume of Compugen Ltd?
plus_minus_icon
What is today’s market capitalisation of Compugen Ltd?
plus_minus_icon
What is the 52-Week High and Low Range of Compugen Ltd?
plus_minus_icon
What percentage is Compugen Ltd down from its 52-Week High?
plus_minus_icon
What percentage is Compugen Ltd up from its 52-Week Low?
plus_minus_icon
Current Price
$0.98
$0.02
(1.86%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00